Charles Schwab’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $181K | Sell |
45,182
-77,108
| -63% | -$308K | ﹤0.01% | 3382 |
|
|
2025
Q1 | $111K | Sell |
122,290
-20,868
| -15% | -$19K | ﹤0.01% | 3333 |
|
|
2024
Q4 | $397K | Hold |
143,158
| – | – | ﹤0.01% | 3207 |
|
|
2024
Q3 | $749K | Hold |
143,158
| – | – | ﹤0.01% | 3012 |
|
|
2024
Q2 | $638K | Buy |
143,158
+16,623
| +13% | +$74.1K | ﹤0.01% | 3090 |
|
|
2024
Q1 | $969K | Buy |
126,535
+4,885
| +4% | +$37.4K | ﹤0.01% | 2807 |
|
|
2023
Q4 | $518K | Buy |
121,650
+27,655
| +29% | +$118K | ﹤0.01% | 3065 |
|
|
2023
Q3 | $395K | Buy |
93,995
+5,738
| +7% | +$24.1K | ﹤0.01% | 3128 |
|
|
2023
Q2 | $492K | Buy |
88,257
+71,708
| +433% | +$399K | ﹤0.01% | 3063 |
|
|
2023
Q1 | $94.8K | Hold |
16,549
| – | – | ﹤0.01% | 3257 |
|
|
2022
Q4 | $17.4K | Hold |
16,549
| – | – | ﹤0.01% | 3512 |
|
|
2022
Q3 | $45K | Hold |
16,549
| – | – | ﹤0.01% | 3351 |
|
|
2022
Q2 | $79K | Sell |
16,549
-13,948
| -46% | -$66.6K | ﹤0.01% | 3309 |
|
|
2022
Q1 | $125K | Sell |
30,497
-5,930
| -16% | -$24.3K | ﹤0.01% | 3384 |
|
|
2021
Q4 | $249K | Hold |
36,427
| – | – | ﹤0.01% | 3323 |
|
|
2021
Q3 | $423K | Sell |
36,427
-25,490
| -41% | -$296K | ﹤0.01% | 3192 |
|
|
2021
Q2 | $1.06M | Buy |
61,917
+2,422
| +4% | +$41.3K | ﹤0.01% | 2906 |
|
|
2021
Q1 | $1.18M | Buy |
59,495
+10,450
| +21% | +$207K | ﹤0.01% | 2800 |
|
|
2020
Q4 | $1.01M | Buy |
49,045
+711
| +1% | +$14.7K | ﹤0.01% | 2763 |
|
|
2020
Q3 | $1.27M | Buy |
+48,334
| New | +$1.27M | ﹤0.01% | 2618 |
|